主动监测用于中危前列腺癌:系统综述与汇总分析
该系统综述与荟萃分析纳入18项研究、3783例经选择的中危前列腺癌患者,评估主动监测结局。汇总的主动监测未终止生存率3年为70%、5年为63%、10年为53%;GG≥3升级无生存率3年为84%、5年为78%。活检GG1与GG2间主动监测终止无显著差异(HR 1.08, 95%CI 0.86-1.35)。
要点
- 中危前列腺癌主动监测5年未终止生存率63%,10年降至53%。
- GG≥3升级无生存率3年84%、5年78%,mpMRI筛查队列更高。
- 活检GG1与GG2的主动监测终止风险无显著差异。
核心结论
- 尽管缺乏长期肿瘤学结局数据,越来越多证据提示主动监测在经过良好选择的中危前列腺癌患者中肿瘤学上是安全的。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南(PROSPERO CRD420251138532),检索PubMed/MEDLINE、Embase和Web of Science截至2025年9月。
- 共纳入18项研究,包括3783例经选择的中危前列腺癌患者(Gleason Grade Group 1-2)。
主要发现
- 汇总主动监测未终止生存率:3年70%(95%CI 62-78)、5年63%(95%CI 58-68)、10年53%(95%CI 38-67)。
- 限制于GG2队列的汇总估计:3年72%、5年56%、10年40%。
- 所有队列GG≥3升级无生存率:3年84%(95%CI 76-92)、5年78%(95%CI 65-91)。
- 多参数磁共振成像筛查队列GG≥3升级无生存率:3年92%(95%CI 86-98)、5年87%(95%CI 78-95)。
- 活检GG1与GG2之间主动监测终止无显著差异(HR 1.08; 95%CI 0.86-1.35)。
临床怎么用
- 主动监测可考虑用于经良好选择的中危前列腺癌患者(GG1-2),尤其结合多参数磁共振成像进行选择和随访。
局限性
- 纳入研究存在中等偏倚风险且主动监测方案间存在异质性。
- 缺乏长期数据,特别是稳健的肿瘤学结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Active surveillance (AS) is the preferred management for individuals with low-risk prostate cancer (PCa), but its role in intermediate-risk (IR) disease remains underreported. Given growing interest and published data, we performed an updated systematic review and meta-analysis to evaluate AS outcomes in selected patients with Gleason Grade Group (GG) 1-2 IR PCa. METHODS: A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420251138532). PubMed/MEDLINE, Embase, and Web of Science databases were searched for studies published up to September 2025 reporting outcomes of AS in IR PCa. Primary outcomes were AS discontinuation-free survival and GG ≥3 upgrade-free survival. RESULTS: In total, 18 studies, including 3783 selected patients with IR PCa, were analyzed. Pooled AS discontinuation-free survival rates were 70% (95% confidence interval [CI] 62-78) at 3 years, 63% (95% CI 58-68) at 5 years, and 53% (95% CI 38-67) at 10 years. In analyses restricted to GG 2 cohorts, corresponding pooled estimates were 72% at 3 years, 56% at 5 years, and 40% at 10 years. GG ≥3 upgrade-free survival was 84% (95% CI 76-92) at 3 years and 78% (95% CI 65-91) at 5 years in all cohorts and 92% (95% CI 86-98) and 87% (95% CI 78-95) at 3 and 5 years in cohorts screened using multiparametric magnetic resonance imaging. No significant difference in AS discontinuation was observed between biopsy GG 1 and 2 (hazard ratio 1.08; 95% CI 0.86-1.35). Limitations include moderate risk of bias and heterogeneity across AS protocols. CONCLUSIONS: Although long-term data are lacking, particularly regarding robust oncological outcomes, growing evidence suggests that AS appears oncologically safe in well-selected patients. Magnetic resonance imaging will play a key role in the appropriate selection and follow-up of patients.
引用
- Uleri A, Cella L, Long-Depaquit T, et al. Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis. BJU Int. 2026. PMID: 42503039. doi:10.1111/bju.70388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。